FIELD: bioengineering.
SUBSTANCE: options of selected immune body or its fragment are suggested, they are specifically linked with outer domain CXCR5 of person. Described: pharmaceutical composition and options of the patient treatment using said immune body or its fragment for treatment of the disease or state being result of or linked with CXCR5 of person. The selected coding molecule of nucleic acid, expression vector of its bases, and host cell for expression of the immune body or its fragment containing the said vector are suggested.
EFFECT: invention use ensures new immune bodies that are specifically linked with outer domain CXCR5 and block fixation of CXCL13 ligand with CXCR5 of person, this can be used in medicine for treatment of the diseases or disorders linked with or being result of CXCR5.
21 cl, 2 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST CXCR5, THEIR COMPOSITIONS AND USE | 2018 |
|
RU2798422C2 |
| ANTIBODY FORMULATIONS | 2017 |
|
RU2769326C2 |
| IL-4 AND/OR IL-13 BINDING ANTIBODIES AND USING THEM | 2008 |
|
RU2580049C2 |
| ANTIBODIES THAT BIND TO PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) | 2013 |
|
RU2689953C2 |
| THYMIC STROMAL LYMPHOPOIETIN RECEPTOR ANTIBODIES | 2007 |
|
RU2486202C2 |
| CXCL13 ANTAGONISTS AND APPLICATION THEREOF FOR TREATING INFLAMMATORY DISEASES | 2007 |
|
RU2449808C2 |
| MONOCLONAL ANTIBODIES AND METHODS FOR THEIR APPLICATION | 2012 |
|
RU2623122C2 |
| ANTIBODIES TO THE RELATED CANCER-EMBRYONIC ANTIGEN CELL ADHESION MOLECULE (CEACAM) | 2012 |
|
RU2650869C2 |
| INTERFERON ALPHA 1 RECEPTOR ANTIBODIES AND USE THEREOF | 2005 |
|
RU2600884C2 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
